Teva Copaxone Nears U.K. Approval, But NICE To Refuse MS Drug Payment
Executive Summary
Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.